INDSWFTLAB
Ind-Swift Laboratories Limited (INDSWFTLAB) Stock Analysis
Ind-Swift Laboratories Limited manufactures pharmaceutical APIs and formulations for domestic and export markets. It operates in antibiotics and specialty actives for generic drug makers. The company has API plants in India. It is a listed pharma company.
Healthcare › Drug Manufacturers - Specialty & Generic
₹349.10
-0.81% 1W | +223.30% 52W
Market Cap
3.1k CR
P/E Ratio
36.2
52W High
₹426.6
52W Low
₹87.2
Div. Yield
0%
Beta
0.9
50 DMA
₹373
200 DMA
₹228.2
Profit Margin
11.2%
Inst. Own.
6.4%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 310 | 290 | 288 | 529 | 33 | 12 | 129 | 138 | 153 | 153 | 151 | 170 | 191 |
| Expenses | 250 | 224 | 236 | 437 | 43 | 24 | 135 | 147 | 149 | 151 | 147 | 149 | 158 |
| Operating Profit | 60 | 66 | 52 | 91 | -10 | -12 | -7 | -9 | 4 | 1 | 4 | 21 | 33 |
| OPM % | 19% | 23% | 18% | 17% | -29% | -99% | -5% | -7% | 2.4% | 1.0% | 2.8% | 12% | 17% |
| Other Income | 6 | 7 | 7 | 458 | 11 | 13 | 16 | 220 | 15 | 18 | 22 | -3 | 7 |
| Interest | 20 | 21 | 21 | 3 | 0 | 0 | 10 | -27 | 1 | 2 | 1 | -2 | 1 |
| Depreciation | 14 | 13 | 14 | 20 | 0 | 0 | 6 | 7 | 7 | 7 | 9 | 8 | 8 |
| Profit before tax | 32 | 39 | 24 | 527 | 1 | 1 | -7 | 230 | 10 | 10 | 16 | 12 | 33 |
| Tax % | 45% | 18% | 19% | 6% | -3% | 31% | -16% | 4% | 17% | 22% | 42% | -26% | 25% |
| Net Profit | 17 | 32 | 19 | 494 | 1 | 0 | -5 | 222 | 9 | 8 | 10 | 15 | 25 |
| EPS in Rs | 2.92 | 5.36 | 3.29 | 83.55 | 0.16 | 0.07 | -0.93 | 36.67 | 1.45 | 0.98 | 1.17 | 1.74 | 2.84 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 660 | 653 | 716 | 765 | 757 | 780 | 891 | 1,039 | 1,207 | 1,281 | 574 | 649 | 665 |
| Expenses | 571 | 546 | 610 | 631 | 630 | 635 | 709 | 837 | 978 | 1,029 | 581 | 602 | 605 |
| Operating Profit | 89 | 107 | 106 | 134 | 126 | 144 | 183 | 202 | 229 | 252 | -7 | 47 | 60 |
| OPM % | 13% | 16% | 15% | 18% | 17% | 19% | 21% | 19% | 19% | 20% | -1.2% | 7% | 9% |
| Other Income | -31 | 1 | 15 | 16 | 120 | 33 | 23 | 37 | 7 | 434 | 292 | 36 | 44 |
| Interest | 117 | 106 | 88 | 28 | 92 | 107 | 100 | 96 | 92 | 51 | 3 | 1 | 1 |
| Depreciation | 84 | 85 | 88 | 87 | 104 | 90 | 87 | 131 | 57 | 53 | 24 | 31 | 32 |
| Profit before tax | -143 | -83 | -55 | 36 | 50 | -20 | 18 | 13 | 87 | 582 | 258 | 51 | 71 |
| Tax % | -17% | -29% | -29% | 39% | 42% | 7% | 117% | 117% | 45% | 28% | 3% | 15% | |
| Net Profit | -119 | -59 | -39 | 22 | 29 | -21 | -3 | -2 | 48 | 421 | 250 | 43 | 57 |
| EPS in Rs | -29.14 | -14.33 | -8.75 | 4.85 | 6.09 | -3.59 | -0.53 | -0.36 | 8.06 | 71.24 | 41.32 | 4.97 | 6.73 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | -19.0% | -6.0% | 0.0% |
| Profit CAGR | -6.0% | 79.0% | 12.0% |
Shareholding Pattern
Promoters39.49%
FIIs14.80%
DIIs0.68%
Public45.02%
Promoters39.49%
FIIs14.33%
DIIs0.68%
Public45.50%
Promoters43.00%
FIIs13.88%
Public43.14%
Promoters42.93%
FIIs10.70%
DIIs0.17%
Public46.19%
Promoters42.93%
FIIs10.90%
DIIs0.15%
Public46.01%
Promoters42.01%
DIIs19.49%
Public38.52%
Promoters42.01%
FIIs0.26%
DIIs8.03%
Public49.72%
Promoters40.94%
FIIs3.07%
DIIs0.91%
Public55.08%
Promoters43.00%
FIIs13.88%
Public43.14%
Promoters42.93%
FIIs10.90%
DIIs0.15%
Public46.01%
INDSWFTLAB
Holdings Analysis
Key strengths & risk signals
56
Overall
41
Fundamental
72
Technical
Risks (3)
Cannot calculate PEG - insufficient growth data.
RECOVERY MODE! Current price (349.1) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -0.8% (1 week), -3.3% (1 month), 22.6% (3 months).
Strengths (4)
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
BULLISH TREND! 50-day average (373.0) is above 200-day average (228.2) - positive signal.
EXCELLENT YEAR! Stock gained 223.3% in the last year.
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 696,908 vs down days: 564,718. Ratio: 1.23x
Fundamental & Technical Analysis
56Overall
41Fundamental
72Technical
Fundamental Breakdown
Growth Quality
4/30
Revenue CAGR: -19.7% (DECLINING, 2/15). Profit CAGR: -3.2% (DECLINING, 2/15).
Profit Margin
5/10
DECENT EFFICIENCY! 11.2% profit margin - acceptable profitability.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.02 - excellent financial health.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 38.44% public ownership - moderate retail influence.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (373.0) is above 200-day average (228.2) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (349.1) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 223.3% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 696,908 vs down days: 564,718. Ratio: 1.23x
RSI
3/5
NEUTRAL! RSI at 41.9 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 77.2% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -0.8% (1 week), -3.3% (1 month), 22.6% (3 months).
Beta
4/5
BELOW MARKET! Beta of 0.90 - slightly less volatile than market.
INDSWFTLAB
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q2FY272026-11-10 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INDSWFTLAB | ₹349.10 | 36.2 | 11.2% | -19.7% | -3.2% | +223.3% | 56 | BREAKDOWN | +327.5% | +38.5% | +51.6% | +25.6% |
| SOLARA | ₹648.00 | 84.1 | 2.4% | -1.2% | – | +18.7% | 50 | BREAKDOWN | -382.2% | +74.8% | +33.1% | +9.4% |
| HIKAL | ₹225.40 | – | -0.3% | -5.4% | – | -5.0% | 62 | BREAKOUT | -67.0% | -151.4% | +7.7% | -22.7% |
| UNICHEMLAB | ₹509.10 | 11.8 | 14.3% | 18.4% | – | +8.8% | 63 | BREAKDOWN | -495.2% | +280.7% | +20.1% | +10.0% |
| SAKAR | ₹1,028.70 | 74.8 | 14.2% | 22.0% | 23.0% | +153.7% | 74 | BREAKDOWN | +112.8% | -9.1% | +38.5% | +2.7% |
| KPL | ₹3,856.40 | 49.4 | 14.6% | 26.1% | 51.5% | +4.3% | 70 | APPROACHING RESISTANCE | +115.1% | +1.2% | +45.7% | +3.4% |
| HESTERBIO | ₹2,308.90 | 14.3 | 41.1% | 7.7% | 27.8% | +46.2% | 72 | APPROACHING RESISTANCE | +491.5% | +506.3% | -8.2% | -22.9% |
| WINDLAS | ₹974.20 | 31.2 | 6.7% | 20.7% | 16.0% | +19.8% | 74 | BREAKDOWN | 0.0% | +10.6% | +18.1% | +4.0% |
Data from TradeAlone · Updated daily
INDSWFTLAB News
